Polymorphism of MTHFR and MTRR in Czech patients with cardiovascular diseases and stroke

Cesko-Slovenska Pediatrie

Volumn 58, Issue 7, 2003, Pages 418-420

  Matalon, R ^a   Rady, S ^b   Szucs, K ^b   Matalon, P ^b   Hyanek J ^b   Sebesta P ^b   Matouskova J ^b   Vondrackova N ^b   Pejznochova H ^b   Dubska L ^b   Prindisova H ^b   Dvorakova J ^b   Loucka M ^b   Martinikova V ^b   Slancova M ^b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CYTOSINE; FOLIC ACID; METHIONINE SYNTHASE; METHIONINE SYNTHASE REDUCTASE; THIAMINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CZECHOSLOVAKIA; ENZYME POLYMORPHISM; FEMALE; HUMAN; HYPERHOMOCYSTEINEMIA; INCIDENCE; MALE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STROKE; VITAMIN SUPPLEMENTATION;

EID: 0042023524     PISSN: 00692328     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Alfthan, G., Pekkanen, J., Jauhiainen, M. et al.: Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis, 106, 1994, p. 9-19.
2. Arnesen, E., Refsum, H., Bonaa, K. H. et al.: Serum total homocysteine and coronary heart disease. Int. J. Epidemiol., 24, 1995, p. 704-709.
3. Brugada, R., Marian, A. J.: A common mutation in methylenetetrahydrofolate reductase gene is not a major risk of coronary artery disease. Circulation, 128, 1997, p. 107-112.
4. Clarke, R., Daly, L., Robinson, K. et al.: Hyperhomocysteinemia: an independent risk factor for vascular disease. New Engl. J. Med., 324, 1991, p. 1149-1155.
5. Genest, J. J. Jr., McNamara, J. R., Salem, D. N. et al.: Plasma homocyst(e)ine levels in men with premature coronary artery disease. J. Amer. Coll. Cardiol., 16, 1990, p. 1114-1119.
6. The European Atherosclerosis Research Study (EARS): Design and Objectives. Int. J. Epidemiol., 23, 1994, p. 465-471.
7. Engbersen, A. M., Franken, D. G., Boers, G. H. et al.: Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Amer. J. Hum. Genet., 56, 1995, p. 142-150.
8. Frosst, P., Blom, H. J., Milos, R. et al.: A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat. Genet., 10, 1995, p. 111-113.
9. Gudnason, V., Stansbie, D., Scott, J. et al.: C677T (thermolabile alanine/valine) polymorphism in methylenetetrahydrofolate reductase (MTHFR): its frequency and impact on plasma homocysteine concentration in different European populations. Atherosclerosis, 136, 1998, p. 347-354.
10. Guttormsen, A. B., Ueland, P. M., Nesthus, I. et al.: Determinants and vitamin responsiveness of intermediate hyperhomocysteinemia (> 40 μmol/l). The Hordaland homocysteine study. J. Clin. Invest., 98, 1996, p. 2174-2183.
11. Harmon, D. L., Woodside, J. V., Yarnell, J. W. G., MacMaster, D. et al.: The common "thermolabile" variant of methylenetetrahydrofolate reductase is a major determinant of mild hyperhomocysteinemia. Q. J. Med., 89, 1996, p. 571-577.
12. Jacques, P. F., Bostom, A. G., Williams, R. R. et al.: Relation between folate status, a common mutation in methylenetetrahydrofolate reductase and plasma homocysteine concentrations. Circulation, 93, 1996, p. 7-9.
13. Kang, S. S., Wong, P. W., Bock, H. G. et al.: Intermediate hyperhomocysteinemia resulting from compound heterozygozity of methylenetetrahydrofolate reductase mutations. Amer. J. Hum. Genet., 48, 1991, p. 546-551.
14. Kluijtmans, L. A., v. den Heuvel, L. P., Boers, G. H. et al.: Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Amer. J. Hum. Genet. 58, 1996, p. 35-41.
15. Ma, J., Stampfer, M. J., Hennekens, C. H. et al.: Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine and risk of myocardial infarction in US physicians. Circulation, 94, 1996, p. 1812-1814.
16. Malinow, M. R., Kang, S. S., Taylor, L. M. et al.: Prevalence of hyperhomocyst(e)inemia in patients with peripheral occlusive disease. Circulation. 87, 1989, p. 1180-1188.
17. Motulsky, A. G.: Nutritional ecogenetics: homocysteine-related arteriosclerotic vascular disease, neural tube defects and folic acid. Amer. J. Hum. Genet., 58, 1996, p. 17-20.
18. Mudd, S. H., Levy, H. L., Kraus, J. P.: Disorders of transsulfuration. In: Scriver, C. R., Beaudet, A. L., Sly, W. S., Walle, D. (Eds.): The Metabolic and Molecular Bases of Inherited Diseases. 8th ed. New York, McGraw-Hill 2001, p. 2007-2057.
19. Nygard, O., Vollset, S. E. et al.: Total plasma homocysteine and cardiovascular risk profile: The Hordaland Homocysteine Study. JAMA, 274, 1995, p. 1526-1533.
20. Rady, P. L., Szucs, S., Grady, J., Hudnall, S. D., Kellner, L. H., Nitowsky, H., Tyring, S. K., Matalon, R. B.: Genetic polymorphisms of methylenetetrahydrofolate reductase (MTHFR) and methionine synthase reductase (MTRR) in ethnic populations in Texas; a report of a novel MTHFR polymorphic site, G1793A. Amer. J. Med. Genet., in press.
21. Stampfer, M. J., Malinow, M. R., Willet, W. C. et al.: A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA, 268, 1993, p. 877-881.
22. van der Put, N. M., Gabreels, F., Stevens, E. M., Smeitink, J. A., Trijbels, F. J., Eskes, T. K., van den Heuvel, L. P., Blom, J. H.: A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Amer. J. Hum. Genet., 62, 1998, p. 1044-1051.
23. Wilcken, D. E., Wilcken, B.: The pathogenesis of coronary artery disease. A possible role for methionine metabolism. J. Clin. Invest., 57, 1976, p. 1079-1082.
24. Wilcken, D. E., Wang, X. L., Sim, A. S., McRedie, R. M.: Distribution in healthy and coronary population of the methylenetetrahydrofolate reductase (MTHFR) 677 C> T mutation. Arterioscler. Thromb. Vasc. Biol., 16, 1996, p. 878-882.
25. 12) increases risk for spina bifida. Mol. Genet. Metab., 4, 1999, p. 317-323.